We are live on ! Find out more
CRNX icon

Crinetics Pharmaceuticals
CRNX

58 hedge funds and large institutions have $440M invested in Crinetics Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 24 increasing their positions, 11 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 11

92% more capital invested

Capital invested by funds: $229M → $440M (+$211M)

29% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 7

9.41% more ownership

Funds ownership: 62.95% → 72.36% (+9.4%)

5% less funds holding

Funds holding: 61 → 58 (-3)

Holders
58
Holders Change
-3
Holders Change %
-4.92%
% of All Funds
1.14%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
9
Increased
24
Reduced
11
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
+$2.09M
2
OM
Opaleye Management
Massachusetts
+$1.13M
3
State Street
State Street
Massachusetts
+$387K
4
California Public Employees Retirement System
California Public Employees Retirement System
California
+$364K
5
Northern Trust
Northern Trust
Illinois
+$244K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$4.42M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.87M
3
Goldman Sachs
Goldman Sachs
New York
-$1.09M
4
Marshall Wace
Marshall Wace
United Kingdom
-$829K
5
Millennium Management
Millennium Management
New York
-$706K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
51
Citigroup
New York
$56K +$20.3K +1,067 +90%
Ensign Peak Advisors
52
Ensign Peak Advisors
Utah
$55K +$42K +2,208 New
Legal & General Group
53
Legal & General Group
United Kingdom
$54K +$7.98K +419 +23%
BNP Paribas Financial Markets
54
BNP Paribas Financial Markets
France
$40.7K +$1.07K +56 +4%
Bank of Montreal
55
Bank of Montreal
Ontario, Canada
$35K +$8.28K +435 +45%
AIP
56
Ameritas Investment Partners
Nebraska
$24K – – –
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$12K +$1.28K +67 +16%
Canada Life
58
Canada Life
Manitoba, Canada
$11K +$8.66K +455 New
Goldman Sachs
59
Goldman Sachs
New York
– -$1.09M -72,640 Closed
Marshall Wace
60
Marshall Wace
United Kingdom
– -$829K -55,112 Closed
HSBC Holdings
61
HSBC Holdings
United Kingdom
– -$183K -12,197 Closed
MWNA
62
Marshall Wace North America
New York
– -$45K -2,965 Closed
TRCT
63
Tower Research Capital (TRC)
New York
– -$40K -2,691 Closed
AIC
64
Ameritas Investment Company
Nebraska
– -$3K -160 Closed
Daiwa Securities Group
65
Daiwa Securities Group
Japan
– -$2K -153 Closed
1 2
3

CRNX Hedge Fund Activity: Q4 2019 in Review

58 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q4 2019, worth a combined $440M — up 92% from $229M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new CRNX positions and 7 closed out — a net gain of 2 holders — while 24 added to existing stakes and 11 trimmed.

The largest buyer was Polar Capital, adding an estimated $2.09M. The largest seller was BlackRock, cutting an estimated $4.42M.

  • 58 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q4 2019, down from 61 in Q3 2019.
  • Funds reported $440M of Crinetics Pharmaceuticals stock for Q4 2019, up 92% quarter-over-quarter.
  • 9 funds opened new Crinetics Pharmaceuticals positions in Q4 2019 and 7 closed out, a net change of +2 holders.
  • The largest Crinetics Pharmaceuticals buyer in Q4 2019 was Polar Capital, an estimated $2.09M added.
  • The largest Crinetics Pharmaceuticals seller in Q4 2019 was BlackRock, an estimated $4.42M sold.

Based on aggregated 13F filings for Q4 2019.